Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
复制标题
DOI：
10.1182/blood-2018-06-858613
复制
发表时间：
2018-12-06
期刊：
影响因子：
20.3
通讯作者：
Munshi, Nikhil
中科院分区：
文献类型：
--
作者：
Perrot, Aurore;Lauwers-Cances, Valerie;Munshi, Nikhil
新型药物的引入使多发性骨髓瘤患者的临床结局得到了重大改善。为了缩短新疗法的评估时间，卫生机构目前正在研究将微小残留病（MRD）作为临床试验的替代终点。我们评估了MRD的预后价值，在维持治疗期间通过下一代测序（NGS）进行测量。MRD阴性定义为在100万个骨髓细胞中不存在肿瘤浆细胞（
The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (